catherine orrell
catherine orrell
Professor, Desmond Tutu HIV Centre, University of Cape Town
Verified email at
Cited by
Cited by
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of …
MA Thompson, MJ Mugavero, KR Amico, VA Cargill, LW Chang, R Gross, ...
Annals of internal medicine 156 (11), 817-833, 2012
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design
SD Lawn, L Myer, C Orrell, LG Bekker, R Wood
Aids 19 (18), 2141-2148, 2005
Adherence is not a barrier to successful antiretroviral therapy in South Africa
C Orrell, DR Bangsberg, M Badri, R Wood
Aids 17 (9), 1369-1375, 2003
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ...
New England Journal of Medicine 384 (11), 1003-1014, 2021
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial
I Sanne, C Orrell, MP Fox, F Conradie, P Ive, J Zeinecker, M Cornell, ...
The Lancet 376 (9734), 33-40, 2010
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation
SD Lawn, L Myer, G Harling, C Orrell, LG Bekker, R Wood
Clinical infectious diseases 43 (6), 770-776, 2006
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality
MWG Brinkhof, A Boulle, R Weigel, E Messou, C Mathers, C Orrell, ...
PLoS medicine 6 (4), e1000066, 2009
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non …
ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, ...
The Lancet 396 (10267), 1994-2005, 2020
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa
LG Bekker, L Myer, C Orrell, S Lawn, R Wood
South African medical journal 96 (4), 315-320, 2006
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority …
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 5 (5), e211-e220, 2018
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa
K Kranzer, J Zeinecker, P Ginsberg, C Orrell, NN Kalawe, SD Lawn, ...
PloS one 5 (11), e13801, 2010
Improving antiretroviral therapy adherence in resource‐limited settings at scale: a discussion of interventions and recommendations
JE Haberer, L Sabin, KR Amico, C Orrell, O Galárraga, AC Tsai, ...
African Journal of Reproduction and Gynaecological Endoscopy 20 (1), 2017
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority …
ENCORE1 Study Group
The Lancet 383 (9927), 1474-1482, 2014
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited
C Orrell, G Harling, SD Lawn, R Kaplan, M McNally, LG Bekker, R Wood
Antiviral therapy 12 (1), 83-88, 2007
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort
A Boulle, C Orrell, R Kaplan, G Van Cutsem, M McNally, K Hilderbrand, ...
Antiviral therapy 12 (5), 753-760, 2007
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared
O Keiser, C Orrell, M Egger, R Wood, MWG Brinkhof, H Furrer, ...
PLoS medicine 5 (7), e148, 2008
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme
SD Lawn, LG Bekker, L Myer, C Orrell, R Wood
Aids 19 (17), 2050-2052, 2005
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa
MD Nglazi, SD Lawn, R Kaplan, K Kranzer, C Orrell, R Wood, LG Bekker
JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (1), e1-e8, 2011
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa
SD Lawn, F Little, LG Bekker, R Kaplan, E Campbel, C Orrell, R Wood
Aids 23 (3), 335-342, 2009
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors
K Kranzer, JJ Lewis, N Ford, J Zeinecker, C Orrell, SD Lawn, LG Bekker, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (3), e17-e23, 2010
The system can't perform the operation now. Try again later.
Articles 1–20